The quest for new cysteinyl-leukotriene and lipoxin receptors: Recent clues

Pharmacology and Therapeutics

Volumn 103, Issue 1, 2004, Pages 81-94

  Norel, Xavier ^a   Brink, Charles ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

5 lipoxygenase; 5 LO; ALX receptor; Ang II; angiotensin II; aspirin triggered lipoxin (15 epi LXA4); ATL; BAY u9773; cys LT 2 receptor; cys LT1 receptor; Cysteinyl leukotrienes; Lipoxins

Indexed keywords

1 [2 METHOXY 4 [(PHENYLSULFONYLAMINO)CARBONYL]BENZYL] 1H INDAZOLE 6 CARBAMIC ACID CYCLOPENTYL ESTER; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO]PHENYL] 4 HYDROXY 3 METHYLBUTYRIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; LIGAND; LIPID; LIPOXIN; LIPOXIN RECEPTOR A 4; LIPOXIN RECEPTOR B 4; PEPTIDOLEUKOTRIENE; PEPTIDOLEUKOTRIENE RECEPTOR 1; PEPTIDOLEUKOTRIENE RECEPTOR 2; POBILUKAST; RECEPTOR; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZM 198615;

BLOOD; CELLULAR DISTRIBUTION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; HUMAN; INFLAMMATION; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; REVIEW; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CYSTEINE; HUMANS; INFLAMMATION MEDIATORS; LEUKOTRIENES; RECEPTORS, LIPOXIN;

EID: 3042750458     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2004.05.003     Document Type: Review

References (117)

1. Allen S.P., Chester A.H., Piper P.J., Sampson A.P., Akl E.S., Yacoub M.H. Effects of leukotrienes C4 and D4 on human isolated saphenous veins. Br J Clin Pharmacol. 34:1992;409-414
2. Allen S.P., Dashwood M.R., Chester A.H., Tadjkarimi S., Collins M., Piper P.J., Yacoub M.H. Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4. Cardioscience. 4:1993;47-54
3. Allen S.P., Chester A.H., Dashwood M.R., Tadjkarimi S., Piper P.J., Yacoub M.H. Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery. Implications for graft performance. Circulation. 90:1994;515-524
4. Allen S.P., Dashwood M.R., Morrison K., Yacoub M.H. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation. 97:1998;2406-2413
5. Ariel A., Chiang N., Arita M., Petasis N.A., Serhan C.N. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol. 170:2003;6266-6272
6. Bäck M., Norel X., Walch L., Gascard J., de Montpreville V., Dahlen S., Brink C. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol. 401:2000;389-395
7. Bäck M., Norel X., Walch L., Gascard J., Mazmanian G., Dahlen S., Brink C. Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol. 401:2000;381-388
8. Badr K.F., DeBoer D.K., Schwartzberg M., Serhan C.N. Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc Natl Acad Sci USA. 86:1989;3438-3442
9. 2 or lipoxin A4 in human neutrophils. Mol Pharmacol. 64:2003;721-730
10. Baker S.R., Boot J.R., Jamieson W.B., Osborne D.J., Sweatman W.J.F. The comparative in vitro pharmacology of leukotriene D4 and its isomers. Biochem Biophys Res Commun. 103:1981;1258-1264
11. Bandeira-Melo C., Weller P.F. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids. 69:2003;135-143
12. Bandeira-Melo C., Phoofolo M., Weller P.F. Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C4 production in eosinophils and basophils. J Biol Chem. 276:2001;22779-22787
13. Bandeira-Melo C., Woods L.J., Phoofolo M., Weller P.F. Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med. 196:2002;841-850
14. Baud L., Koo C.H., Goetzl E.J. Specificity and cellular distribution of human polymorphonuclear leucocyte receptors for leukotriene C4. Immunology. 62:1987;53-59
15. Beckman B.S., Despinasse B.P., Spriggs L. Actions of lipoxins A4 and B4 on signal transduction events in Friend erythroleukemia cells. Proc Soc Exp Biol Med. 201:1992;169-173
16. Bond R.A., Leff P., Johnson T.D., Milano C.A., Rockman H.A., McMinn T.R., Apparsundaram S., Hyek M.F., Kenakin T.P., Allen L.F., Lefkowitz R.J. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature. 374:1995;272-276
17. Brady H.R., Persson U., Ballermann B.J., Brenner B.M., Serhan C.N. Leukotrienes stimulate neutrophil adhesion to mesangial cells: Modulation with lipoxins. Am. J. Physiol. 259:1990;F809-F815
18. Brezinski M.E., Gimbrone M.A., Nicolaou K.C., Serhan C.N. Lipoxins stimulate prostacyclin generation by human endothelial cells. FEBS Lett. 245:1989;167-172
19. Brink C., Dahlen S.E., Drazen J., Evans J.F., Hay D.W., Nicosia S., Serhan C.N., Shimizu T., Yokomizo T. International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev. 55:2003;195-227
20. Brink C., Dahlen S.E., Drazen J., Evans J.F., Hay D.W., Rovati G.E., Serhan C.N., Shimizu T., Yokomizo T. International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol Rev. 56:2004;149-157
21. Buckner C.K., Krell R.D., Laravuso R.B., Coursin D.B., Bernstein P.R., Will J.A. Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4. J Pharmacol Exp Ther. 237:1986;558-562
22. Chan C.C., Ecclestone P., Nicholson D.W., Metters K.M., Pon D.J., Rodger I.W. Leukotriene D4-induced increases in cytosolic calcium in THP-1 cells: dependence on extracellular calcium and inhibition with selective leukotriene D4 receptor antagonists. J Pharmacol Exp Ther. 269:1994;891-896
23. Chiang N., Gronert K., Clish C., O'Brien J., Freeman M., Serhan C. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest. 104:1999;309-316
24. Chiang N., Fierro I.M., Gronert K., Serhan C.N. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med. 191:2000;1197-1208
25. Chiono M., Heller R.S., Andazola J.J., Herman C.A. Leukotriene C4 binds to receptors and has positive inotropic effects in bullfrog heart. J Pharmacol Exp Ther. 256:1991;1042-1048
26. Chiono M., Andazola J.J., Torres O.A., Herman C.A. Characterization and localization of leukotriene C4 receptors in bullfrog lung. J Pharmacol Exp Ther. 262:1992;1248-1255
27. Choi J.H., Park H.S., Oh H.B., Lee J.H., Suh Y.J., Park C.S., Shin H.D. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: An association with a haplotype of 5-lipoxygenase. Hum. Genet. 114:2004;337-344
28. Christie P.E., Spur B.W., Lee T.H. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am Rev Respir Dis. 145:1992;1281-1284
29. Christophe T., Karlsson A., Rabiet M.J., Boulay F., Dahlgren C. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 56:2002;470-476
30. Colgan S.P., Serhan C.N., Parkos C.A., Delp-Archer C., Madara J.L. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest. 92:1993;75-82
31. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 46:1994;205-229
32. Cotecchia S., Exum S., Caron M.G., Lefkowitz R.J. Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci USA. 87:1990;2896-2900
33. Cramer E.B., Pologe L., Pawlowski N.A., Cohn Z.A., Scott W.A. Leukotriene C promotes prostacyclin synthesis by human endothelial cells. Proc Natl Acad Sci USA. 80:1983;4109-4113
34. Dahlen S.E., Raud J., Serhan C.N., Bjork J., Samuelsson B. Biological activities of lipoxin A include lung strip contraction and dilation of arterioles in vivo. Acta Physiol Scand. 130:1987;643-647
35. Dahlen S.E., Franzen L., Raud J., Serhan C.N., Westlund P., Wikstrom E., Bjorck T., Matsuda H., Webber S.E., Veale C.A., Puustinen T., Haeggström J., Nicolaou K.C., Samuelsson B. Actions of lipoxin A4 and related compounds in smooth muscle preparations and on the microcirculation in vivo. Adv Exp Med Biol. 229:1988;107-130
36. Datta Y.H., Romano M., Jacobson B.C., Golan D.E., Serhan C.N., Ewenstein B.M. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation. 92:1995;3304-3311
37. Devchand P.R., Hihi A.K., Perroud M., Schleuning W.D., Spiegelman B.M., Wahli W. Chemical probes that differentially modulate peroxisome proliferator-activated receptor alpha and BLTR, nuclear and cell surface receptors for leukotriene B(4). J Biol Chem. 274:1999;23341-23348
38. Devchand P.R., Arita M., Hong S., Bannenberg G., Moussignac R.L., Gronert K., Serhan C.N. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17:2003;652-659
39. Drazen J.M., Austen K.F., Lewis R.A., Clark D.A., Goto G., Marfat A., Corey E.J. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA. 77:1980;4354-4358
40. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., Lusis A.J., Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 350:2004;29-37
41. Eppihimer M.J., Russell J., Anderson D.C., Epstein C.J., Laroux S., Granger D.N. Modulation of P-selectin expression in the postischemic intestinal microvasculature. Am. J. Physiol. 273:1997;G1326-G1332
42. Fierro I.M., Kutok J.L., Serhan C.N. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther. 300:2002;385-392
43. Fierro I.M., Colgan S.P., Bernasconi G., Petasis N.A., Clish C.B., Arita M., Serhan C.N. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J Immunol. 170:2003;2688-2694
44. Fiore S., Ryeom S.W., Weller P.F., Serhan C.N. Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J Biol Chem. 267:1992;16168-16176
45. Fiore S., Romano M., Reardon E.M., Serhan C.N. Induction of functional lipoxin A4 receptors in HL-60 cells. Blood. 81:1993;3395-3403
46. Fiore S., Maddox J.F., Perez H.D., Serhan C.N. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med. 180:1994;253-260
47. Fleisch J.H., Rinkema L.E., Baker S.R. Evidence for multiple leukotriene D4 receptors in smooth muscle. Life Sci. 31:1982;577-581
48. Gewirtz A.T., Collier-Hyams L.S., Young A.N., Kucharzik T., Guilford W.J., Parkinson J.F., Williams I.R., Neish A.S., Madara J.L. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol. 168:2002;5260-5267
49. Gronert K., Martinsson-Niskanen T., Ravasi S., Chiang N., Serhan C.N. Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. Am J Pathol. 158:2001;3-9
50. Hardy G., Stanke-Labesque F., Peoc'h M., Hakim A., Devillier P., Caron F., Morel S., Faure P., Halimi S., Bessard G. Cysteinyl leukotrienes modulate angiotensin II constrictor effects on aortas from streptozotocin-induced diabetic rats. Arterioscler Thromb Vasc Biol. 21:2001;1751-1758
51. He R., Sang H., Ye R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood. 101:2003;1572-1581
52. Heise C.E., O'Dowd B.F., Figueroa D.J., Sawyer N., Nguyen T., Im D.S., Stocco R., Bellefeuille J.N., Abramovitz M., Cheng R., Williams D.L. Jr., Zeng Z., Liu Q., Ma L., Clements M.K., Coulombe N., Liu Y., Austin C.P., George S.R., O'Neill G.P., Metters K.M., Lynch K.R., Evans J.F. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem. 275:2000;30531-30536
53. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., Samani N.J., Gudmundsson G., Grant S.F., Thorgeirsson G., Sveinbjornsdottir S., Valdimarsson E.M., Matthiasson S.E., Johannsson H., Gudmundsdottir O., Gurney M.E., Sainz J., Thorhallsdottir M., Andresdottir M., Frigge M.L., Topol E.J., Kong A., Gudnason V., Hakonarson H., Gulcher J.R., Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 36:2004;233-239
54. Heller R.S., Herman R.P., Herman C.A. The action and metabolism of peptide leukotrienes in the isolated bullfrog lung. Can J Physiol Pharmacol. 67:1989;309-314
55. Jozsef L., Zouki C., Petasis N.A., Serhan C.N., Filep J.G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA. 99:2002;13266-13271
56. Jones T.R., Zamboni R., Belley M., Champion E., Charette L., Ford-Hutchinson A.W., Frenette R., Gauthier J.Y., Leger S., Masson P., McFarlane C.S., Piechuta H., Rokach J., Williams H., Young R.N. Pharmacology of L-660, 711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol. 67:1989;17-28
57. Kamohara M., Takasaki J., Matsumoto M., Matsumoto S., Saito T., Soga T., Matsushime H., Furuichi K. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells. Biochem Biophys Res Commun. 287:2001;1088-1092
58. Koshino T., Takano S., Houjo T., Sano Y., Kudo K., Kihara H., Kitani S., Takaishi T., Hirai K., Ito K., Morita Y. Expression of 5-lipoxygenase and 5-lipoxygenase-activating protein mRNAs in the peripheral blood leukocytes of asthmatics. Biochem Biophys Res Commun. 247:1998;510-513
59. Koshino T., Takano S., Kitani S., Ohshima N., Sano Y., Takaishi T., Hirai K., Yamamoto K., Morita Y. Novel polymorphism of the 5-lipoxygenase activating protein (FLAP) promoter gene associated with asthma. Mol Cell Biol Res Commun. 2:1999;32-35
60. Krell R.D., Tsai B.S., Berdoulay A., Barone M., Giles R.E. Heterogeneity of leukotriene receptors in guinea-pig trachea. Prostaglandins. 25:1983;171-178
61. Labat C., Ortiz J.L., Norel X., Gorenne I., Verley J., Abram T.S., Cuthbert N.J., Tudhope S.R., Norman P., Gardiner P., Brink C. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther. 263:1992;800-805
62. Lee T.H., Horton C.E., Kyan-Aung U., Haskard D., Crea A.E., Spur B.W. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin Sci (Colch). 77:1989;195-203
63. Le Y., Murphy P.M., Wang J.M. Formyl-peptide receptors revisited. Trends Immunol. 23:2002;541-548
64. Lefer A.M., Stahl G.L., Lefer D.J., Brezinski M.E., Nicolaou K.C., Veale C.A., Abe Y., Smith J.B. Lipoxins A4 and B4: comparison of eicosanoids having bronchoconstrictor and vasodilator actions but lacking platelet aggregatory activity. Proc Natl Acad Sci USA. 85:1988;8340-8344
65. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2:2001;612-619
66. Lotzer K., Spanbroek R., Hildner M., Urbach A., Heller R., Bretschneider E., Galczenski H., Evans J.F., Habenicht A.J. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arterioscler Thromb Vasc Biol. 23:2003;E32-E36
67. Lynch K.R., O'Neill G.P., Liu Q., Im D.S., Sawyer N., Metters K.M., Coulombe N., Abramovitz M., Figueroa D.J., Zeng Z., Connolly B.M., Bai C., Austin C.P., Chateauneuf A., Stocco R., Greig G.M., Kargman S., Hooks S.B., Hosfield E., Williams D.L. Jr., Ford-Hutchinson A.W., Caskey C.T., Evans J.F. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 399:1999;789-793
68. Maddox J.F., Colgan S.P., Clish C.B., Petasis N.A., Fokin V.V., Serhan C.N. Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity. FASEB J. 12:1998;487-494
69. Maderna P., Godson C., Hannify G., Murphy M., Brady H.R. Influence of lipoxin A4 and other lipoxygenase-derived eicosanoids on tissue factor expression. Am J Physiol. 279:2000;C945-C953
70. McLeod J.D., Piper P.J. Effect of ICI 198, 615, SK+F 104, 353, MK-571 and CGP45715A on cysteinyl leukotriene-induced responses in guinea-pig heart. Prostaglandins. 41:1991;395-406
71. McMahon B., Stenson C., McPhillips F., Fanning A., Brady H.R., Godson C. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J Biol Chem. 275:2000;27566-27575
72. Mechiche H., Candenas L., Pinto F.M., Nazeyrollas P., Clement C., Devillier P. Characterization of cysteinyl leukotriene receptors on human saphenous veins: antagonist activity of montelukast and its metabolites. J Cardiovasc Pharmacol. 43:2004;113-120
73. Mehta P., Mehta J., Lawson D., Krop I., Letts L.G. Leukotrienes potentiate the effects of epinephrine and thrombin on human platelet aggregation. Thromb Res. 41:1986;731-738
74. Mellor E.A., Maekawa A., Austen K.F., Boyce J.A. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA. 98:2001;7964-7969
75. Mellor E., Austen K.F., Boyce J.A. Cysteinyl leukotriene and uridine diphosphate induce cytokine generation by human mast cells through an interlukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J Exp Med. 195:2002;583-592
76. Milano C.A., Dolber P.C., Rockman H.A., Bond R.A., Venable M.E., Allen L.F., Lefkowitz R.J. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA. 91:1994;10109-10113
77. Nielsen C.K., Ohd J.F., Wikstrom K., Massoumi R., Paruchuri S., Juhas M., Sjolander A. The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. Adv Exp Med Biol. 525:2003;201-204
78. 3H]leukotriene C4 to guinea-pig lung membranes. The lack of correlation of LTC4 functional activity with binding affinity. Eur J Pharmacol. 143:1987;323-334
79. 3H]leukotriene D4 binding to guinea-pig lung membranes. The correlation of binding affinity with activity on the guinea-pig ileum. Eur J Pharmacol. 182:1990;301-312
80. Nothacker H.P., Wang Z., Zhu Y., Reinscheid R.K., Lin S.H., Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 58:2000;1601-1608
81. Ohd J.F., Wikstrom K., Sjolander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology. 119:2000;1007-1018
82. Ohd J.F., Nielsen C.K., Campbell J., Landberg G., Lofberg H., Sjolander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology. 124:2003;57-70
83. Ortiz J.L., Gorenne I., Cortijo J., Seller A., Labat C., Sarria B., Abram T.S., Gardiner P.J., Morcillo E., Brink C. Leukotriene receptors on human pulmonary vascular endothelium. Br J Pharmacol. 115:1995;1382-1386
84. Panettieri R.A., Tan E.M., Ciocca V., Luttmann M.A., Leonard T.B., Hay D.W. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am J Respir Cell Mol Biol. 19:1998;453-461
85. Papayianni A., Serhan C.N., Brady H.R. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J Immunol. 156:1996;2264-2272
86. Parameswaran K., Cox G., Radford K., Janssen L.J., Sehmi R., O'Byrne P.M. Cysteinyl leukotrienes promote human airway smooth muscle migration. Am J Respir Crit Care Med. 166:2002;738-742
87. Pedersen K.E., Bochner B.S., Undem B.J. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. J Pharmacol Exp Ther. 281:1997;655-662
88. Peters-Golden M., Brock T.G. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 487:2001;323-326
89. Planaguma A., Titos E., Lopez-Parra M., Gaya J., Pueyo G., Arroyo V., Claria J. Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. FASEB J. 16:2002;1937-1939
90. Popov G.K., Nekrasov A.S., Khshivo A.L., Pochinskii A.G., Lankin V.Z. [Effects of lipoxin B on colony-forming capacity of human peripheral blood mononuclear cells in diffusion chambers] PG-80-3. Biull Eksp Biol. 1989;107
91. Porreca E., Di Febbo C., Di Sciullo A., Angelucci D., Nasuti M., Vitullo P., Reale M., Conti P., Cuccurullo F., Poggi A. Cysteinyl leukotriene D4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost. 76:1996;99-104
92. Qiu F.H., Devchand P.R., Wada K., Serhan C.N. Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils. FASEB J. 15:2001;2736-2738
93. Ravasi S., Capra V., Mezzetti M., Nicosia S., Rovati G.E. A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. Mol Pharmacol. 57:2000;1182-1189
94. Ravasi S., Capra V., Panigalli T., Rovati G.E., Nicosia S. Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 63:2002;1537-1546
95. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 122:1993;518-523
96. 2+ mobilization. J Immunol. 157:1996;2149-2154
97. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237:1987;1171-1176
98. Sarau H.M., Ames R.S., Chambers J., Ellis C., Elshourbagy N., Foley J.J., Schmidt D.B., Muccitelli R.M., Jenkins O., Murdock P.R., Herrity N.C., Halsey W., Sathe G., Muir A.I., Nuthulaganti P., Dytko G.M., Buckley P.T., Wilson S., Bergsma D.J., Hay D.W. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 56:1999;657-663
99. Saussy D.L. Jr., Sarau H.M., Foley J.J., Mong S., Crooke S.T. Mechanisms of leukotriene E4 partial agonist activity at leukotriene D4 receptors in differentiated U-937 cells. J Biol Chem. 264:1989;19845-19855
100. Schaldach C.M., Riby J., Bjeldanes L.F. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry. 38:1999;7594-7600
101. Schellenberg R.R., Foster A. Differential activity of leukotrienes upon human pulmonary vein and artery. Prostaglandins. 27:1984;475-482
102. Serhan C.N. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta. 1212:1994;1-25
103. Sjostrom M., Johansson A.S., Schroder O., Qiu H., Palmblad J., Haeggstrom J.Z. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 23:2003;E37-E41
104. Snyder D.W., Krell R.D. Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea. J Pharmacol Exp Ther. 231:1984;616-622
105. Spanbroek R., Grabner R., Lotzer K., Hildner M., Urbach A., Ruhling K., Moos M.P., Kaiser B., Cohnert T.U., Wahlers T., Zieske A., Plenz G., Robenek H., Salbach P., Kuhn H., Radmark O., Samuelsson B., Habenicht A.J. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA. 100:2003;1238-1243
106. Stanke-Labesque F., Devillier P., Bedouch P., Cracowski J.L., Chavanon O., Bessard G. Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition. Cardiovasc Res. 47:2000;376-383
107. Takano T., Fiore S., Maddox J.F., Brady H.R., Petasis N.A., Serhan C.N. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 185:1997;1693-1704
108. Takano T., Clish C.B., Gronert K., Petasis N., Serhan C.N. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest. 101:1998;819-826
109. Takasaki J., Kamohara M., Matsumoto M., Saito T., Sugimoto T., Ohishi T., Ishii H., Ota T., Nishikawa T., Kawai Y., Masuho Y., Isogai T., Suzuki Y., Sugano S., Furuichi K. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun. 274:2000;316-322
110. Thivierge M., Doty M., Johnson J., Stankova J., Rola-Pleszczynski M. IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. J Immunol. 165:2000;5221-5226
111. Thompson M.D., van's Gravesande K.S., Galczenski H., Siminovitch K.A., Zamel N., Slutsky A., Drazen J.M., George S.R., Burnham W.M., Evans J.F., O'Dowd B.F. A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha. Pharmacogenetics. 13:2003;641-649
112. Tsopanoglou N.E., Pipili-Synetos E., Maragoudakis M.E. Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction. Eur J Pharmacol. 258:1994;151-154
113. Tudhope S.R., Cuthbert N.J., Abram T.S., Jennings M.A., Maxey R.J., Thompson A.M., Norman P., Gardiner P.J. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol. 264:1994;317-323
114. Walch L., Norel X., Back M., Gascard J.P., Dahlen S.E., Brink C. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br J Pharmacol. 137:2002;1339-1345
115. Wikstrom K., Ohd J.F., Sjolander A. Regulation of leukotriene-dependent induction of cyclooxygenase-2 and Bcl-2. Biochem Biophys Res Commun. 302:2003;330-335
116. Wikstrom Jonsson E., Rosenqvist U., Dahlen S.E. Agonist and antagonist activities of the leukotriene analogue BAY u9773 in guinea pig lung parenchyma. Eur J Pharmacol. 357:1998;203-211
117. Zellner J.L., Cook J.A., Reines D.H., Wise W.C., Smith E.F. III, Kessler L.D., Halushka P.V. Hemodynamic effects of leukotriene (LT) D4 and a LTD4 receptor antagonist in the pig. Eicosanoids. 3:1990;219-224